HT-2157
 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C21H13F3N2O |
| Molar mass | 366.335 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
HT-2157 (former code name SNAP-37889) is a drug which acts as a selective non-peptide antagonist for the receptor GAL-3, which is usually activated by the neuropeptide galanin. Blocking this receptor with HT-2157 produced increased serotonin release,[1] as well as producing antidepressant and anxiolytic effects in animal studies,[2] and it was also being researched for treatment of cognitive dysfunction.[3] All human clinical trials were terminated due to safety concerns however, and new GAL-3 antagonists are now being sought instead.[4]
References
- ^ Rowley HL, et al. Effects of HT 2157, a galanin 3 receptor antagonist, on extracellular levels of 5 HT in various brain regions of freely moving rats. Proceedings of the British Pharmacological Society Winter Meeting December 2005
- ^ Swanson CJ, et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. PNAS 2005; 102(48):17489-17494. doi 10.1073/pnas.0508970102
- ^ Kaplan AP. Enteric-coated HT-2157 compositions and methods of their use. Patent US 8277842, filed Jan 20th 2012.
- ^ http://www.dartneuroscience.com/DrugPrograms.php
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |